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Polysaccharide sidechains attached to proteins play important roles in cell–cell and receptor–ligand inter-
actions. Variation in the carbohydrate component has been extensively studied for the iron transport protein
transferrin, because serum levels of the transferrin isoforms asialotransferrin 1 disialotransferrin (carbo-
hydrate-deficient transferrin, CDT) are used as biomarkers of excessive alcohol intake. We conducted a
genome-wide association study to assess whether genetic factors affect CDT concentration in serum.
CDT was measured in three population-based studies: one in Switzerland (CoLaus study, n 5 5181) and
two in Australia (n 5 1509, n 5 775). The first cohort was used as the discovery panel and the latter ones
served as replication. Genome-wide single-nucleotide polymorphism (SNP) typing data were used to identify
loci with significant associations with CDT as a percentage of total transferrin (CDT%). The top three SNPs in
the discovery panel (rs2749097 near PGM1 on chromosome 1, and missense polymorphisms rs1049296,
rs1799899 in TF on chromosome 3) were successfully replicated , yielding genome-wide significant combined
association with CDT% (P 5 1.9 3 1029, 4 3 10239, 5.5 3 10243, respectively) and explain 5.8% of the variation
in CDT%. These allelic effects are postulated to be caused by variation in availability of glucose-1-phosphate
as a precursor of the glycan (PGM1), and variation in transferrin (TF) structure.
INTRODUCTION
Many proteins undergo N- or O-glycosylation during or
immediately after peptide synthesis. Glycosylation of proteins
modifies their physicochemical properties and plays an impor-
tant role in receptor–ligand and cell–cell interactions (1). It
has been estimated that half of all proteins are glycoproteins
(2). Some proteins show variation in their glycosylation; the
glycosylation sites may or may not be occupied (3), the carbo-
hydrate structure can vary, and this variation can affect func-
tion. Conditions leading to variation in protein glycosylation
include congenital disorders of glycosylation (4), infection,
inflammation and cancers. In principle, variation in protein
glycosylation could reflect genetic or acquired variation in
(i) the enzymes which carry out the multiple steps of attach-
ment, extension and modification of the glycan, (ii) the
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target or substrate protein which is to be glycosylated, (iii) the
‘quality control’ mechanisms which check and if necessary
recycle proteins, or (iv) the turnover or repair of
glycosylated proteins after their initial synthesis.
Variation in the glycosylation of transferrin has been
extensively studied because of the role of plasma transferrin
in iron transport, and because the concentration or proportion
of less-glycosylated transferrin isoforms (asialotransferrin
and disialotransferrin, collectively known as carbohydrate-
deficient transferrin, CDT) can serve as a biomarker of
excessive alcohol consumption. Circulating transferrin can
vary between the asialo- and octasialo- isoforms, with
tetrasialotransferrin the most abundant (5).
Up to 40% of genetic variation in total transferrin levels is
due to variants in the transferrin (TF) and hemochromatosis
(HFE) genes (6), but whether transferrin glycosylation is
also gene dependent has never been assessed. In this study,
we first tested whether TF gene polymorphisms have signifi-
cant effects on CDT concentration or CDT as a percentage
of total transferrin (CDT%). We then conducted a genome-
wide search for polymorphisms affecting CDT, tested replica-
tion of significant or suggestive findings with independent
cohorts and meta-analysed the combined dataset. In this
work, we used data from three studies measuring CDT in
different ways, which allows assessment of the robustness of
allelic associations across methods.
Identification of significant allelic associations for transfer-
rin glycosylation has the potential to improve clinical
interpretation of CDT% as a diagnostic aid in the management
of alcohol use disorders, through estimation of genotype-
specific reference ranges. This would also provide proof of
principle for potential allelic effects on other diagnostic glyco-
protein measurements, such as tumour markers; and it has
theoretical implications for genetic variation in the control
of post-translational modification of proteins.
RESULTS
Relevant subject characteristics, for both the Swiss (CoLaus)
and Australian participants, are summarized in Table 1.
Correlations between CDT results for two occasions 10
years apart were estimated from data for 66 Australian partici-
pants with both CDTect and N-Latex results. The repeatability
of this measure was 0.59 for CDT concentration and 0.63
for CDT%, and these correlations were only slightly reduced
by adjustment for sex and reported alcohol consumption.
Heritability estimates, derived from sibling correlations in
the second Australian (N-Latex) study, were 0.59 for CDT
concentration and 0.60 for CDT%.
Genome-wide association results for CDT percentage
In our genome-wide association study (GWAS), two regions
showed significant associations with CDT% (Supplementary
Material, Fig. S1). These were on chromosomes 1 and 3,
within or close to the PGM1 and TF genes, respectively.
Both loci fulfilled the selection criteria listed in Materials
and Methods, with lead single-nucleotide polymorphisms
(SNPs) rs2749097 (P ¼ 3.15 × 1026) and rs1534166 (P ¼
1 × 10238) in the discovery set. In the latter region, both the
association and the linkage disequilibrium (LD) were so
strong that we performed step-wise model selection in order
not to miss imperfect tagging or allelic heterogeneity in the
region. This analysis led to the most plausible association
model, which included three non-synonymous SNPs:
rs1799899 (TF Gly277Ser, P ¼ 3.35 × 10235), rs1049296
(TF Pro589Ser, P ¼ 2.13 × 10232), rs8177318 (TF
Ser55Arg, P ¼ 3.58 × 1024). This result indicates that the
original strongest association with rs1534166 was tagging
multiple missense variants in the transferrin gene. Therefore,
we selected rs2749097 (PGM1, chromosome 1) and the
three non-synonymous SNPs in TF for in silico replication.
The hit on chromosome 1 (rs2749097) was confirmed in
both replication cohorts
(P ¼ 0.0068 and P ¼ 0.0018) in a direction-consistent
manner, yielding a combined P-value of 1.9 × 1029 (Fig. 1A).
Two of the three non-synonymous markers (rs1799899 and
rs1049296) successfully replicated in the N-Latex-based
Australian cohort (P ¼ 9.7 × 1026, P ¼ 7.1 × 10213, respect-
ively), giving rise to very significant meta P-values (P ¼ 4 ×
10239, P ¼ 5.5 × 10243). The third SNP (rs8177318) showed
a direction-consistent replication signal, but—consistent with
the weaker initial association and the smaller replication
sample size—could not reach nominally significant replication
P-value.
The association results for the significant chromosome 3
region are shown in Figure 1B, where initial GWAS-
significant associations were found across a range of genes
and intergenic regions between BFSP2 and RAB6B, with the
most significant SNP (rs1534166, P ¼ 4.3 × 10246) being in
Table 1. Studies and participants. All studies were population-based, but in the second Australian study subjects reporting high alcohol intake were prioritised for
CDT measurement. In the table R stands for Pearson correlation, P for P value, N for sample size, and SD for standard deviation
CDT method CoLaus Australia, 1993–96 Australia, 2004–06
Capillary electrophoresis Mini-column (CDTect) Immunoassay (N-Latex CDT)
n (male, female) with CDT in units/l 690 (338, 352) 1400 (539, 861) 2087 (1000, 1087)
n (male, female) with CDT in percent 5909 (2815, 3094) 1353 (514, 839) 2087 (1000, 1087)
n (male, female) with CDT% and genome-wide SNP data 5181 (2454, 2727) 745 (169, 576) 1509 (764, 745)
Drinks per week (Mean, SD, Range) 7.0+9.1 (0–80) 6.8+9.0 (0–70) 24.4+23.1 (0–315)
CDT, percent (Mean, SD) 0.947+0.783 0.614+0.303 1.766+0.649
CDT, units (Mean, SD) 31.2+25.2 17.4+8.9 48.9+17.2
Total transferrin, g/l (Mean, SD) 3.80+0.44 2.85+0.52 2.80+0.41
Correlation, drinks per week versus CDT percent (R, p, N) 0.407, 1.09 × 102234, 5401 0.241, 2.52 × 10219, 1353 0.373, 1.07 × 10267, 2020
Correlation, drinks per week versus CDT units (R, p, N) 0.367, 3.71 × 10225, 690 0.200, 4.15 × 10214, 1400 0.352, 8.07 × 10260, 2020
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SRPRB. In addition, the association results from the con-
ditional analysis (on rs1799899 and rs1049296) clarified that
the associations previously seen in the BFSP2-CDV3-TOPBP1
and RAB6B regions could be ascribed to LD with the TF
SNPs. Results are summarized in Table 2 and shown in
more detail in Supplementary Material, Table S1.
Since CDT% is correlated with transferrin levels, we
investigated whether SNPs associated with CDT% also show
association when CDT% is conditioned on transferrin levels.
Although associations became slightly less significant, effect
sizes remained unchanged (t-test P-value . 0.75 for all
SNPs). Thus, we consider that these genetic associations
hold independently of the total transferrin level.
We also checked association P-values for these two TF SNPs
(rs1534166 and rs1799899) in the other Australian replication
cohort, but the results from the CDTect method showed an
Figure 1. Local plots for the two regions associated with CDT%. The y-axis shows significance of the association as –log10(P), x-axis is physical distance (on
Build 36). Shading of the data points indicates the strength of LD with the most significant SNP in the region. (A) SNP associations with CDT (as a percentage of
total transferrin) near the PGM1 locus on chromosome 1. The plotted combined P-values are from a meta-analysis of the discovery (CoLaus) and both (Aus-
tralian) replication cohorts. (B) Association plot as described above, but for the region near the TF and SRPRB loci on chromosome 3. The plot shows combined
P-values from a meta-analysis of the discovery (CoLaus) and the N-Latex-based (Australian) replication cohorts, showing univariate association results for all
SNPs (red or uncoloured symbols). The three TF SNPs obtained by the multivariate model selection procedure (rs1049296, rs1799899 and rs8177318) are
marked with green boundary circle.
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opposite direction of the allelic effects compared with the other
assessment methods (Phet ¼ 2.64 × 1029). This arises from the
analytical principle of the CDTectmethod, and because changes
in the amino acid sequence of transferrin can alter the isoelectric
point (pI) of the isoforms. A more detailed explanation can be
found in Discussion. For this reason, we excluded the CDTect
replication sample and used only the N-Latex-based replication
data for the chromosome 3 region.
Genome-wide association results for CDT concentration
For CDT concentration, the only significant SNPs were in
the TF-SRPRB region of chromosome 3 (see Table 2). As
for CDT%, the most significant SNP was rs1534166 in
SRPRB (P ¼ 1.6 × 10217). Further, rs1799899 in TF was
independently significant (P ¼ 1.0 × 1029) when the data
were reanalysed after adjustment for the effects of
rs1534166. These P-values were less significant than the
equivalent ones for CDT%, because the number of Swiss par-
ticipants who had total transferrin assessed (from which CDT
concentration could be calculated) was only 690, but the effect
sizes (betas in Table 2) were similar for CDT% and CDT
concentration. Total CDT concentration was more weakly
associated with the CDT%-associated PGM1 polymorphism
(rs2749097) yielding P ¼ 3.99 × 1024.
Genome-wide association results for total transferrin
As previously reported, SNPs in TF andHFE showed significant
effects on total transferrin concentration (see Table 2). However,
theHFE locus had no significant effects on either CDT%orCDT
concentration. Even though the TF SNPsmost strongly affecting
total transferrin concentration showed only low-to-moderate LD
with rs1799899 (r2 ¼ 0.002 for rs6439434 and 0.026 for
rs3811647), the combined association P-value for this SNP
was still highly significant (P ¼ 5.1 × 10212).
Genome-wide association results for total transferrin
The discovered variants explained 5.8% of the variance of
CDT%, 4.9% for CDT levels and 11.2% for transferrin levels.
DISCUSSION
We have found that both the absolute and relative concen-
trations of ‘carbohydrate-deficient’ isoforms of transferrin
are subject to genetic variation. Indeed, comparison of the
heritability and repeatability estimates suggests that all or
nearly all of the repeatable variation is genetic. As explained
in Materials and Methods section, we tried to correct for all
relevant environmental factors (first two principal components
(PCs), sex, smoking status and alcohol consumption) to
maximize our chances to tease out the most important
genetic components determining CDT%. Other factors, such
as pregnancy, haemodialysis, liver disease are either uncom-
mon in the general population (in the CoLaus sample we
had ,11 pregnant women, 7 participants with liver disease
and 9 participants with alcohol problems, ,0.5% of theT
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total) or have negligible effect on CDT levels, thus could not
have considerably influenced CDT levels.
In terms of specific SNPs and genes, there is evidence that
variation near to the PGM1 gene on chromosome 1, and in the
TF gene on chromosome 3, contributes to the overall genetic
effect. This leads us to consider how these genes fit into the
processes of synthesis, release or circulation of the isoforms
of transferrin.
The association with PGM1 may be related to synthesis of
the carbohydrate sidechains, which are attached to the
protein and then modified by removal and addition of carbo-
hydrate groups (7). The phosphoglucomutase enzyme converts
glucose-6-phosphate into glucose-1-phosphate needed for syn-
thesis of UDP-glucose, a precursor of the carbohydrate which
is eventually transferred to the protein (8). However, phospho-
glucomutase catalyses a very early step in this pathway and it
is by no means clear how variation in the PGM1 gene would
affect the carbohydrate structure of the glycoprotein. Major
defects in PGM1 are known (http://www.ncbi.nlm.nih.gov/
omim/171900), but they lead to a form of glycogen storage
disease rather than a carbohydrate-deficient glycoprotein
syndrome. However, PGM1 expression in human liver (9) is
significantly affected by rs4643 at 63 898 026 bp (expression
P ¼ 1.0 × 1026), and this SNP is one of a group of three
affecting CDT% at P , 1028. It is reasonable to accept that
the SNPs on chromosome 1 showing significant association
with CDT affect expression of PGM1 in the liver (the site of
transferrin synthesis), but an understanding of how phospho-
glucomutase activity affects transferrin isoforms will require
experiments which are beyond the scope of this study.
The associations on chromosome 3 aremore readily related to
relevant genes, but the details are complex. Although rs1534166
in SRPRB showed the strongest association (P ¼ 4.3 × 10246)
with CDT% in the initial combined analysis, more detailed
examination of this region showed two independent effects at
neighbouring loci in different exons of TF, rs1799899
(Gly277Ser, P ¼ 3.96 × 10239), and rs1049296 (Pro589Ser,
P ¼ 5.45 × 10243). These associations were identified using
step-wise model selection; hence, each variant is associated
when conditioned on the other one. The SNP rs1799899 had a
substantially greater allelic effect than rs1049296, but was less
common [minor allele frequency (MAF) ¼ 5.8%]. A third non-
synonymous SNP in TF, rs8177318 or Ser55Arg, may also con-
tribute, but this could not be shown at the genome-wide signifi-
cance level. Through this example we illustrate how
computational methods can help in tracking down potentially
causal variants, revealing allelic heterogeneity and substantially
(from 3.6 to 5.8%) increasing the explained variance compared
with univariate analysis.
The effects of these TF polymorphisms remain unchanged
even in association with transferrin-corrected CDT%, so the
significant effects on CDT% cannot be explained as being sec-
ondary to changes in total transferrin concentration. They may
be due to changes in tertiary structure of transferrin because of
the amino acid differences (Pro589Ser from rs1049296 and/or
Gly277Ser from rs1799899), even though these changes are
not at the N-glycosylation sites (which are asparagine residues
at positions 413 and 611).
The heterogeneity of allelic effects across methods at the TF
locus can be ascribed to these non-synonymous coding SNPs
and the difference in analytical principles between the
methods for measurement of CDT. The CDTect method relied
on elution of isoforms with a pI .5.7 from an anion-exchange
column followed by measurement of transferrin in the eluate.
Any changes in the pI of transferrin isoforms resulting from
changes in the amino acid sequence will either increase or
decrease the amount of transferrin eluting from the column.
The effects of the Pro589Ser (or C1/C2) polymorphism in the
transferrin protein on the pI of transferrin and estimated CDT
concentrations were examined by Stibler et al. (10). Although
the effect was not significant with their limited number of
samples, they found mean CDT concentrations of 51, 53 and
58 mg/l for C1, C1/C2 and C2 samples, respectively. The
effects of this variant on the pI of disialotransferrin were illus-
trated by Helander et al. (11). They showed a shift in disialo-
transferrin towards the pI of the more usual forms of mono-
and asialotransferrin in participants with the C2 variant.
Because the CDTect assay measured the sum of asialo-
monosialo- and part of disialotransferrin, the difference in pI
leads to a greater proportion of the disialotransferrin being
measured as CDT and an increase in the apparent CDT concen-
tration. However, both the capillary electrophoresis and the
N-Latex methods showed the effects of rs1049296 and
rs1799899 on CDT which cannot be explained by alteration in
isoelectric point. The N-Latex method is based on a monoclonal
antibody, which specifically recognizes transferrin glycoforms
that lack one or both of the complete N-glycans (disialo-,
monosialo- and asialotransferrins) (12) and does not rely on a
charge-based separation of the isoforms.
Apart from questions of how these polymorphisms affect
serum CDT% or concentration, there may be practical impli-
cations for the diagnostic use of CDT measurement. CDT% is
confirmed to be a robustmarker of various aspects of alcohol con-
sumption in our cohorts: the consumption of beer, wine and sprits
strongly influence CDT% (P, 10258, P, 10257, P, 1026,
respectively), so does alcohol consumption frequency (P,
10267) and total weekly alcohol consumption (P, 102134). As
for any clinical test, it is necessary to establish a reference
range against which patients’ results can be compared. Problems
with CDT as a marker for alcohol consumption have been
reported, thus a definitionof genotype-dependent reference inter-
vals may improve the sensitivity or specificity of this test; this
aspect will be examined in a further paper.
In summary, we have identified two loci (and three indepen-
dent SNPs) affecting the degree of glycosylation of circulating
transferrin through a genome-wide association approach. They
account for 5.8% of phenotypic variation in CDT% or CDT,
which is a high proportion compared with most GWAS
outcomes. These loci require further studies to investigate the
detailed mechanisms. The types of variation, affecting the
process of oligosaccharide synthesis and showing the importance
of protein structure, which we illustrate for transferrin, may well
be relevant to other biologically important glycoproteins.
MATERIALS AND METHODS
Subjects and methods: CoLaus
The design of the CoLaus study has been described previously
(13). Briefly, it is a population-based study conducted between
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2003 and 2006 which recruited over 6000 subjects aged 35–75
years in Lausanne, Switzerland. The following inclusion
criteria were applied: (a) voluntary participation in the exam-
ination, including blood sample, (b) aged 35–75 years and
(c) Caucasian origin defined as having both parents and
grand-parents Caucasian (determined by birth place). The
Institutional Review Board of the Centre Hospitalier Universi-
taire Vaudois (CHUV) in Lausanne and the Cantonal Ethics
Committee approved the study protocol and signed informed
consent was obtained from participants. Participants were
asked to attend the outpatient clinic at the CHUV, Lausanne,
in the morning after an overnight fast. Data were collected
by trained field interviewers during a single visit lasting
60 min. Overall participation rate was 41%.
Most biological assays were performed by the CHUV Clini-
cal Laboratory on fresh blood samples within 2 h of blood
collection, and additional aliquots were stored at –808C.
Transferrin was measured in 690 participants by immunoassay
with maximum inter- and intra-batch CVs of 1.8 and 1.0%,
respectively. CDT measurement was done in a single batch
for 5401 participants by capillary electrophoresis using the
Ceofix-CDT reagent kits for the quantification of CDT in
human serum (Analis, Belgium, kits #10-004760). Separation
was performed on a Beckman P/ACE 5510 System (Beckman
Coulter Instruments, Switzerland) equipped with an ultraviolet
detector set at 200 nm. Maximum intra-batch CV was between
3.8% (highest CDT levels) and 15.3% (lowest CDT levels).
Nuclear DNA was extracted from whole blood for whole-
genome scan analysis using Nucleonw genomic DNA extrac-
tion kit (Tepnel life sciences, Manchester, UK) according to
the manufacturer’s recommendations. Genotyping was per-
formed using the Affymetrix GeneChipw Human Mapping
500K array set, as recommended by the manufacturer. Geno-
types were called using BRLMM (http://www.affymetrix.com/
support/technical/whitepapers/brlmm_whitepaper.pdf) (14).
Duplicate individuals, and first and second degree relatives,
were identified by computing genomic identity-by-descent
coefficients, using PLINK (15). The younger individual from
each duplicate or relative pair was removed. SNPs with call
rate ,70% and individuals with call rate ,90% were
excluded from further analysis.
A set of unmeasured HapMap SNPs was imputed. For
imputation, only autosomal SNPs that were present in
HapMap release 21 were used; the dataset used for imputation
was 5435 unrelated CoLaus individuals and 390 631 measured
SNPs (with Hardy–Weinberg P-value .1027 and MAF
.1%). Imputation was performed using IMPUTE (16)
version 0.2.0, and CEU haplotypes from HapMap release 21,
all downloaded from IMPUTE (http://www.stats.ox.ac.uk/
~marchini/software/gwas/impute.html). For any given SNP,
IMPUTE computed genotype probabilities using information
from all other measured SNPs except the focal SNP. There-
fore, after running IMPUTE, measured SNP genotypes were
used to replace the imputed genotype probabilities. Expected
allele dosages were computed and plugged into the subsequent
association analysis. SNPs with imputation quality (r2-hat)
,0.5 or MAF ,1% were excluded from the analysis.
To account for possible population stratification, we com-
puted PCs using the SMARTPCA (http://genepath.med.harva
rd.edu/~reich/) implementation (17), with default options
except that no outlier removal iterations were performed.
The first two PCs, sex, smoking status and alcohol consump-
tion were used in all adjusted analyses.
Subjects and methods: Australia
Australian subjects participated in one or both of two studies
evaluating the relationship between serum CDT concentration
and alcohol consumption in the general population. All study
participants gave informed consent, and the protocols were
approved by appropriate institutional ethics review commit-
tees.
The first of these (18) was a twin study designed to assess
the heritability of alcohol consumption and alcohol depen-
dence, and to evaluate biochemical effects of excessive
alcohol intake. Telephone interviews were conducted with a
total of 7764 participants and blood was collected from 3375
of them (1134 men and 2241 women) between 1993 and
1996. Secondly, a twin-family study conducted between
2004 and 2006 (19) focused on identification of genetic loci
contributing to susceptibility to alcohol or nicotine depen-
dence, and to liver damage and biochemical abnormalities
among excessive drinkers. Blood was collected from 9031 par-
ticipants (3998 men and 5033 women) aged 18–92 years. In
both studies, participants provided information about their
alcohol use and symptoms associated with alcohol dependence
as part of a telephone interview, and at the time of blood col-
lection they completed a 7-day retrospective diary of alcohol
use.
In the first study, CDT was measured on 1400 people aged
29–92 years (539 men and 861 women; the mean ages 44.8
and 46.5, respectively) using the Pharmacia CDTect method,
in which CDT isoforms are eluted from an anion-exchange
column and measured by immunoassay of transferrin. The
CDTect method may be subject to bias due to polymorphisms
in the TF gene that affect the pI of transferrin (for details, see
Discussion), thus it can be unreliable for associations with TF
SNPs. Therefore, we ignored association results for this cohort
for the TF region. In the second study, CDT was measured in
all available samples from participants who reported alcohol
intake greater than recommended limits of 40 g/day for men
and 20 g/day for women (n ¼ 1173; 634 men and 539
women) and in 915 participants (367 men and 548 women)
who reported lower or no alcohol intake. Serum CDT concen-
tration was measured with a direct immunoassay (12)
(N-Latex CDT method, Siemens Healthcare Diagnostics) on
a Dade BN-II nephelometric analyser. CDT was also calcu-
lated as a percentage of total transferrin (CDT%). One result
with very low total transferrin was excluded as a probable
error or outlier.
Genome-wide SNP genotyping on DNA extracted from
blood samples was performed using Illumina Human610-
Quadv1 chips (582 000 SNPs) or HumanCNV370-Quadv3
chips (351 000 SNPs). SNPs were included in the analyses
if they met the following conditions: Hardy–Weinberg equili-
brium test P ≥ 1026, MAF ≥ 1%, call-rate ≥ 0.95 and the
mean value of GenCall score ≥0.7. Subjects found to be of
non-European ancestry by PC analysis (EIGENSTRAT) (20)
of the genotyping data were also excluded. The PC analysis
used a set of 276 891 autosomal SNPs that were common to
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Australian samples, HapMap 3 (11 global populations) and 5
Northern European (Denmark, Finland, the Netherlands, the
UK and Sweden) populations from the GenomEUtwin Consor-
tium. We excluded 277 individuals who were .6 SD from the
mean of PCs 1 and 2 derived from the European populations.
Imputation of non-genotyped HapMap SNPs was per-
formed. Because imputation is sensitive to both missingness
and SNP density, to avoid introducing bias to the imputed
data, a set of SNPs common to the genotyping chips (n ¼
269 840) was used for imputation. Imputation was undertaken
for 17 862 individuals participating in multiple twin and twin-
family studies conducted at the Queensland Institute of
Medical Research, after population outliers had been
removed, as a single population. The imputation was run in
two stages using Mach (21) (http://www.sph.umich.edu/csg/a
becasis/MACH/index.html). Following imputation, data for
2.54 million Hapmap SNPs were available. The complete
description of the initial quality controls of the GWAS data
and imputation was given by Medland et al. (22). The best
guess genotypes were used for the association analyses if
they met the same conditions as mentioned for the genotyped
SNPs as well as an imputation quality, r2-hat of 0.3 or greater.
Association analyses taking account of family relationships
were conducted using MERLIN (http://www.sph.umich.edu/
csg/abecasis/Merlin/). CDT measurements and genome-wide
SNP data were both available for 2284 subjects (775 with
CDT measured by CDTect and 1509 by N-Latex). Prior to
association analyses, the phenotypes were log-transformed,
normalized to have zero mean and unit variance and adjusted
for the effects of sex, age, self-reported smoking status,
alcohol intake (number of drinks in the seven days preceding
blood collection) and PCs 1 and 2 from the PC analysis. Visu-
alization and annotation of the GWAS results were performed
in WGAViewer (http://people.genome.duke.edu/~dg48/
WGAViewer/download.php) (23).
Replication and meta-analysis
SNPs with association P-value ,5 × 1026 (in the Swiss
discovery cohort), imputation quality (r2-hat) .0.5 and
MAF . 1% were selected, and evaluated in the replication
cohorts. The selection procedure excluded all variants
that had a stronger association signal in their 0.2 cM
neighbourhood.
To dissect multiple independent association signals in
regions with tight LD and strong association signal (e.g. the
TF and HFE genes), we applied a step-wise model selection.
The forward–backward step-wise model selection procedure
started from the empty model (including non-genetic covari-
ates only). In each step of the model selection, we tried to
add (forward) or remove (backward) a SNP to maximize the
Bayesian Information Criterion (BIC) (24) in a greedy
fashion until (local) maximum is reached. If, in the procedure,
only forward steps occurred, we called it conditional analysis,
as simply the most associated variant(s) was/were included as
covariate(s) in a conditional regression model. For associ-
ations with CDT and transferrin concentrations only forward
steps were needed, while for CDT percentage it was a truly
forward–backward model selection.
The results from the discovery and replication cohorts were
combined into a fixed-effects meta-analysis using inverse var-
iance weighting. Tests for heterogeneity were assessed using
Cochran’s Q statistic. As explained above, association
results for the CDTect cohort for the TF region were
ignored, thus the heterogeneity P values for that locus were
computed based on two cohorts only. The details of the tech-
nical explanation for this artefact can be found in Discussion.
Using only two cohorts for this region is not a limitation: the
discovery P values for this locus were ,2 × 10232, so
showing successful replication in only one replication cohort
(N-Latex) is sufficiently convincing.
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